Advertisement
Screener

Verastem, Inc. (VSTM) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

Verastem, Inc. Operating Expenses

Verastem, Inc. (VSTM) reported Operating Expenses of $36.34 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.

Discontinued › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2019-05-09

  • Verastem, Inc. operating expenses for the quarter ending 2019-03-31 was $36.34M, a 75.04% increase year-over-year.
  • Verastem, Inc. operating expenses for the quarter ending 2018-12-31 was $35.47M, a 96.48% increase year-over-year.
  • Verastem, Inc. operating expenses for the quarter ending 2018-09-30 was $37.08M, a 60.25% increase year-over-year.
  • Verastem, Inc. operating expenses for the quarter ending 2018-06-30 was $28.19M, a 109.36% increase year-over-year.
  • Verastem, Inc. operating expenses for fiscal 2018 was $121.50M, a 79.19% increase from fiscal 2017.
  • Verastem, Inc. operating expenses for fiscal 2017 was $67.80M, a 83.24% increase from fiscal 2016.
  • Verastem, Inc. operating expenses for fiscal 2016 was $37.00M, a 36.42% decline from fiscal 2015.
  • Verastem, Inc. operating expenses for fiscal 2015 was $58.20M, a 8.57% increase from fiscal 2014.
Period endOperating Expenses 3 monthOperating Expenses 5 monthOperating Expenses 6 monthOperating Expenses 9 monthOperating Expenses 12 monthOperating Expenses 20 monthOperating Expenses 23 monthOperating Expenses 26 monthOperating Expenses 29 monthOperating Expenses 32 monthOperating Expenses 35 monthOperating Expenses 38 monthOperating Expenses 41 monthOperating Expenses 44 month
2019-03-31$36.34M
10-Q · filed 2019-05-09
$71.81M
derived: sum of 2 quarters · filed 2019-05-09
$108.89M
derived: sum of 3 quarters · filed 2019-05-09
$137.08M
derived: sum of 4 quarters · filed 2019-05-09
2018-12-31$35.47M
10-K · filed 2019-03-12
$72.55M
derived: sum of 2 quarters · filed 2019-03-12
$100.74M
derived: sum of 3 quarters · filed 2019-03-12
$121.50M
10-K · filed 2019-03-12
2018-09-30$37.08M
10-K · filed 2019-03-12
$65.27M
derived: sum of 2 quarters · filed 2019-03-12
$86.03M
10-Q · filed 2018-11-07
$104.08M
derived: sum of 4 quarters · filed 2019-05-09
2018-06-30$28.19M
10-K · filed 2019-03-12
$48.95M
10-Q · filed 2018-08-08
$67.01M
derived: sum of 3 quarters · filed 2019-05-09
$90.14M
derived: sum of 4 quarters · filed 2019-05-09
2018-03-31$20.76M
10-Q · filed 2019-05-09
$38.81M
derived: sum of 2 quarters · filed 2019-05-09
$61.95M
derived: sum of 3 quarters · filed 2019-05-09
$75.42M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$18.05M
10-K · filed 2019-03-12
$41.19M
derived: sum of 2 quarters · filed 2019-03-12
$54.66M
derived: sum of 3 quarters · filed 2019-03-12
$67.80M
10-K · filed 2019-03-12
2017-09-30$23.14M
10-K · filed 2019-03-12
$36.60M
derived: sum of 2 quarters · filed 2019-03-12
$49.75M
10-Q · filed 2018-11-07
$61.55M
derived: sum of 4 quarters · filed 2019-03-12
2017-06-30$13.47M
10-K · filed 2019-03-12
$26.61M
10-Q · filed 2018-08-08
$38.41M
derived: sum of 3 quarters · filed 2019-03-12
$46.47M
derived: sum of 4 quarters · filed 2019-03-12
2017-03-31$13.15M
10-K · filed 2019-03-12
$24.95M
derived: sum of 2 quarters · filed 2019-03-12
$33.01M
derived: sum of 3 quarters · filed 2019-03-12
$41.72M
derived: sum of 4 quarters · filed 2019-03-12
2016-12-31$11.80M
10-K · filed 2018-03-13
$19.86M
derived: sum of 2 quarters · filed 2018-03-13
$28.57M
derived: sum of 3 quarters · filed 2018-03-13
$37.00M
10-K · filed 2019-03-12
2016-09-30$8.06M
10-K · filed 2018-03-13
$16.77M
derived: sum of 2 quarters · filed 2018-03-13
$25.20M
10-Q · filed 2017-11-07
$37.16M
derived: sum of 4 quarters · filed 2018-03-13
2016-06-30$8.71M
10-K · filed 2018-03-13
$17.14M
10-Q · filed 2017-08-08
$29.10M
derived: sum of 3 quarters · filed 2018-03-13
$44.64M
derived: sum of 4 quarters · filed 2018-03-13
2016-03-31$8.43M
10-K · filed 2018-03-13
$20.39M
derived: sum of 2 quarters · filed 2018-03-13
$35.93M
derived: sum of 3 quarters · filed 2018-03-13
$51.39M
derived: sum of 4 quarters · filed 2018-03-13
2015-12-31$11.96M
10-K · filed 2017-03-23
$27.50M
derived: sum of 2 quarters · filed 2017-03-23
$42.96M
derived: sum of 3 quarters · filed 2017-03-23
$58.20M
10-K · filed 2018-03-13
2015-09-30$15.53M
10-K · filed 2017-03-23
$31.00M
derived: sum of 2 quarters · filed 2017-03-23
$46.24M
10-Q · filed 2016-11-07
$60.24M
derived: sum of 4 quarters · filed 2017-03-23
2015-06-30$15.46M
10-K · filed 2017-03-23
$30.70M
10-Q · filed 2016-08-08
$44.70M
derived: sum of 3 quarters · filed 2017-03-23
$58.09M
derived: sum of 4 quarters · filed 2017-03-23
2015-03-31$15.24M
10-K · filed 2017-03-23
$29.24M
derived: sum of 2 quarters · filed 2017-03-23
$42.63M
derived: sum of 3 quarters · filed 2017-03-23
$55.72M
derived: sum of 4 quarters · filed 2017-03-23
2014-12-31$14.00M
10-K · filed 2016-03-03
$27.39M
derived: sum of 2 quarters · filed 2016-03-03
$40.47M
derived: sum of 3 quarters · filed 2016-03-03
$53.61M
10-K · filed 2017-03-23
2014-09-30$13.39M
10-K · filed 2016-03-03
$26.48M
derived: sum of 2 quarters · filed 2016-03-03
$39.61M
10-Q · filed 2015-11-09
$51.00M
derived: sum of 4 quarters · filed 2016-03-03
2014-06-30$13.09M
10-K · filed 2016-03-03
$26.22M
10-Q · filed 2015-08-10
$37.61M
derived: sum of 3 quarters · filed 2016-03-03
$48.26M
derived: sum of 4 quarters · filed 2016-03-03
2014-03-31$13.13M
10-K · filed 2016-03-03
$24.53M
derived: sum of 2 quarters · filed 2016-03-03
$35.17M
derived: sum of 3 quarters · filed 2016-03-03
$45.45M
derived: sum of 4 quarters · filed 2016-03-03
$101.25M
10-Q · filed 2014-05-08
2013-12-31$11.39M
10-K · filed 2015-03-10
$22.04M
derived: sum of 2 quarters · filed 2015-03-10
$32.32M
derived: sum of 3 quarters · filed 2015-03-10
$41.40M
10-K · filed 2016-03-03
$88.11M
10-K · filed 2014-03-06
2013-09-30$10.64M
10-K · filed 2015-03-10
$20.93M
derived: sum of 2 quarters · filed 2015-03-10
$30.01M
10-Q · filed 2014-10-30
$37.98M
derived: sum of 4 quarters · filed 2015-03-10
$76.72M
10-Q · filed 2013-11-12
2013-06-30$10.28M
10-K · filed 2015-03-10
$19.36M
10-Q · filed 2014-08-07
$27.34M
derived: sum of 3 quarters · filed 2015-03-10
$37.77M
derived: sum of 4 quarters · filed 2015-03-10
$66.08M
10-Q · filed 2013-08-13
2013-03-31$9.08M
10-K · filed 2015-03-10
$17.06M
derived: sum of 2 quarters · filed 2015-03-10
$27.49M
derived: sum of 3 quarters · filed 2015-03-10
$34.38M
derived: sum of 4 quarters · filed 2015-03-10
$55.79M
10-Q · filed 2013-05-09
2012-12-31$7.98M
10-K · filed 2014-03-06
$18.41M
derived: sum of 2 quarters · filed 2014-03-06
$25.30M
derived: sum of 3 quarters · filed 2014-03-06
$32.23M
10-K · filed 2015-03-10
$46.71M
10-K · filed 2013-03-26
2012-09-30$10.43M
10-K · filed 2014-03-06
$17.33M
derived: sum of 2 quarters · filed 2014-03-06
$24.25M
10-Q · filed 2013-11-12
$30.27M
derived: sum of 4 quarters · filed 2014-03-06
$38.74M
10-Q · filed 2012-11-13
2012-06-30$6.90M
10-K · filed 2014-03-06
$13.82M
10-Q · filed 2013-08-13
$19.84M
derived: sum of 3 quarters · filed 2014-03-06
$23.89M
derived: sum of 4 quarters · filed 2014-03-06
$28.31M
10-Q · filed 2012-08-13
2012-03-31$6.93M
10-K · filed 2014-03-06
$12.95M
derived: sum of 2 quarters · filed 2014-03-06
$17.00M
derived: sum of 3 quarters · filed 2014-03-06
$19.48M
derived: sum of 4 quarters · filed 2014-03-06
$21.41M
10-Q · filed 2012-05-14
2011-12-31$6.02M
10-K · filed 2013-03-26
$10.07M
derived: sum of 2 quarters · filed 2013-03-26
$12.55M
derived: sum of 3 quarters · filed 2013-03-26
$13.70M
10-K · filed 2014-03-06
2011-09-30$4.05M
10-K · filed 2013-03-26
$6.53M
derived: sum of 2 quarters · filed 2013-03-26
$7.68M
10-Q · filed 2012-11-13
2011-06-30$2.48M
10-K · filed 2013-03-26
$3.63M
10-Q · filed 2012-08-13
2011-03-31$1.15M
10-K · filed 2013-03-26
2010-12-31$784.00K
10-K · filed 2013-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Faeth Therapeutics, Inc. (FTH)United States$0.750B
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Wave Life Sciences, Inc. (WVE)$0.780B-5.56